Which has better earnings & valuation, GDR or VRCI?

Verici Dx has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio genedrive £929K 22.47 -£21.22M -£0.79 N/A Verici Dx £1.91M 2.78 -£6.56M -£2.90 N/A

Is GDR or VRCI more profitable?

Verici Dx has a net margin of -468.31% compared to genedrive's net margin of -500.75%. Verici Dx's return on equity of -178.37% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets genedrive -500.75% -1,044.57% -74.09% Verici Dx -468.31% -178.37% -26.14%

Is YGEN or VRCI more profitable?

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -468.31%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Yourgene Health -27.55% -27.06% -6.71% Verici Dx -468.31% -178.37% -26.14%

Which has better earnings & valuation, AGL or VRCI?

Verici Dx has lower revenue, but higher earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A Verici Dx £1.91M 2.78 -£6.56M -£2.90 N/A

Is AGL or VRCI more profitable?

Verici Dx has a net margin of -468.31% compared to ANGLE's net margin of -732.40%. ANGLE's return on equity of -89.82% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets ANGLE -732.40% -89.82% -29.89% Verici Dx -468.31% -178.37% -26.14%

Which has stronger valuation and earnings, VRCI or GENI?

GENinCode has higher revenue and earnings than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verici Dx £1.91M 2.78 -£6.56M -£2.90 N/A GENinCode £2.91M 2.91 -£6.10M -£2.35 N/A

Is VRCI or GENI more profitable?

GENinCode has a net margin of -170.49% compared to Verici Dx's net margin of -468.31%. Verici Dx's return on equity of -178.37% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -468.31% -178.37% -26.14% GENinCode -170.49% -262.16% -63.99%

Does the media favor VRCI or GENI?

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. GENinCode's average media sentiment score of 0.00 beat Verici Dx's score of -0.97 indicating that GENinCode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative GENinCode 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VRCI or PRM more profitable?

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -468.31%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -468.31% -178.37% -26.14% Proteome Sciences -81.50% 33.80% -19.25%

Does the media prefer VRCI or PRM?

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. Proteome Sciences' average media sentiment score of 0.00 beat Verici Dx's score of -0.97 indicating that Proteome Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Proteome Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Verici Dx (VRCI) Competitors

GBX 0.35 -0.07 (-17.18%)

As of 11:34 AM Eastern

Compare

VRCI vs. GDR, YGEN, AGL, GENI, and PRM

Should you buy Verici Dx stock or one of its competitors? MarketBeat compares Verici Dx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verici Dx include genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), and Proteome Sciences (PRM). These companies are all part of the "diagnostics & research" industry.

How does Verici Dx compare to genedrive?

genedrive (LON:GDR) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Verici Dx has a net margin of -468.31% compared to genedrive's net margin of -500.75%. Verici Dx's return on equity of -178.37% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
genedrive	-500.75%	-1,044.57%	-74.09%
Verici Dx	-468.31%	-178.37%	-26.14%

In the previous week, Verici Dx had 1 more articles in the media than genedrive. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for genedrive. genedrive's average media sentiment score of 0.00 beat Verici Dx's score of -0.97 indicating that genedrive is being referred to more favorably in the media.

Company	Overall Sentiment
genedrive	Neutral
Verici Dx	Negative

genedrive has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.304, meaning that its share price is 30% more volatile than the broader market.

Verici Dx has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
genedrive	£929K	22.47	-£21.22M	-£0.79	N/A
Verici Dx	£1.91M	2.78	-£6.56M	-£2.90	N/A

0.1% of genedrive shares are owned by institutional investors. Comparatively, 14.4% of Verici Dx shares are owned by institutional investors. 4.9% of genedrive shares are owned by company insiders. Comparatively, 1.2% of Verici Dx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Verici Dx beats genedrive on 9 of the 13 factors compared between the two stocks.

How does Verici Dx compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

In the previous week, Verici Dx had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Yourgene Health. Yourgene Health's average media sentiment score of 0.00 beat Verici Dx's score of -0.97 indicating that Yourgene Health is being referred to more favorably in the media.

Company	Overall Sentiment
Yourgene Health	Neutral
Verici Dx	Negative

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 14.4% of Verici Dx shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 1.2% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Yourgene Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.304, suggesting that its stock price is 30% more volatile than the broader market.

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -468.31%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Verici Dx	-468.31%	-178.37%	-26.14%

Verici Dx has lower revenue, but higher earnings than Yourgene Health. Verici Dx is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Verici Dx	£1.91M	2.78	-£6.56M	-£2.90	N/A

Summary

Yourgene Health beats Verici Dx on 8 of the 12 factors compared between the two stocks.

How does Verici Dx compare to ANGLE?

ANGLE (LON:AGL) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Verici Dx had 1 more articles in the media than ANGLE. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for ANGLE. ANGLE's average media sentiment score of 0.20 beat Verici Dx's score of -0.97 indicating that ANGLE is being referred to more favorably in the media.

Company	Overall Sentiment
ANGLE	Neutral
Verici Dx	Negative

Verici Dx has lower revenue, but higher earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
Verici Dx	£1.91M	2.78	-£6.56M	-£2.90	N/A

17.5% of ANGLE shares are held by institutional investors. Comparatively, 14.4% of Verici Dx shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 1.2% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.304, indicating that its share price is 30% more volatile than the broader market.

Verici Dx has a net margin of -468.31% compared to ANGLE's net margin of -732.40%. ANGLE's return on equity of -89.82% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-732.40%	-89.82%	-29.89%
Verici Dx	-468.31%	-178.37%	-26.14%

Summary

Verici Dx beats ANGLE on 7 of the 13 factors compared between the two stocks.

How does Verici Dx compare to GENinCode?

Verici Dx (LON:VRCI) and GENinCode (LON:GENI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

GENinCode has higher revenue and earnings than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£1.91M	2.78	-£6.56M	-£2.90	N/A
GENinCode	£2.91M	2.91	-£6.10M	-£2.35	N/A

14.4% of Verici Dx shares are held by institutional investors. Comparatively, 4.8% of GENinCode shares are held by institutional investors. 1.2% of Verici Dx shares are held by company insiders. Comparatively, 8.6% of GENinCode shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. GENinCode's average media sentiment score of 0.00 beat Verici Dx's score of -0.97 indicating that GENinCode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
GENinCode	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GENinCode has a net margin of -170.49% compared to Verici Dx's net margin of -468.31%. Verici Dx's return on equity of -178.37% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-468.31%	-178.37%	-26.14%
GENinCode	-170.49%	-262.16%	-63.99%

Verici Dx has a beta of 1.304, indicating that its stock price is 30% more volatile than the broader market. Comparatively, GENinCode has a beta of 0.608, indicating that its stock price is 39% less volatile than the broader market.

Summary

GENinCode beats Verici Dx on 7 of the 12 factors compared between the two stocks.

How does Verici Dx compare to Proteome Sciences?

Verici Dx (LON:VRCI) and Proteome Sciences (LON:PRM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. Proteome Sciences' average media sentiment score of 0.00 beat Verici Dx's score of -0.97 indicating that Proteome Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Proteome Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verici Dx has a beta of 1.304, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.224, meaning that its stock price is 78% less volatile than the broader market.

14.4% of Verici Dx shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£1.91M	2.78	-£6.56M	-£2.90	N/A
Proteome Sciences	£3.76M	1.49	-£4.08M	-£1.04	N/A

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -468.31%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-468.31%	-178.37%	-26.14%
Proteome Sciences	-81.50%	33.80%	-19.25%

Summary

Proteome Sciences beats Verici Dx on 8 of the 12 factors compared between the two stocks.

Get Verici Dx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCI vs. The Competition

Export

Metric	Verici Dx	Diagnostics & Research Industry	Medical Sector	LON Exchange
Market Cap	£5.33M	£42.85M	£6.49B	£2.77B
Dividend Yield	N/A	3.34%	2.67%	6.12%
P/E Ratio	-0.12	74.54	23.93	365.21
Price / Sales	2.78	632.71	517.32	87,168.39
Price / Cash	1.31	11.42	42.35	27.85
Price / Book	0.08	3.59	9.73	7.68
Net Income	-£6.56M	£334.07B	£3.56B	£5.89B
7 Day Performance	-18.71%	0.58%	-3.19%	-0.55%
1 Month Performance	-21.78%	-6.44%	-0.11%	3.15%
1 Year Performance	-79.05%	5.63%	25.29%	73.57%

Verici Dx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCI Verici Dx	N/A	GBX 0.35 -17.2%	N/A	-70.1%	£5.33M	£1.91M	N/A	19	News Coverage Gap Down High Trading Volume
GDR genedrive	N/A	GBX 1.33 +4.3%	N/A	-13.8%	£21.35M	£929K	N/A	43
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-70.6%	£7.58M	£2.62M	N/A	650	Gap Up
GENI GENinCode	N/A	GBX 1.03 -2.4%	N/A	-51.7%	£7.43M	£2.91M	N/A	2,300	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:VRCI) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verici Dx (VRCI) Competitors